Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiBladder 1
NCT07424287Phase 3Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2026
- Primary completion
- Jun 2030
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Jul 2026; status: recruiting.
02
Drugs
SHR-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07424287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07424287.